Cargando...
Canagliflozin: a novel treatment option for type 2 diabetes
Type 2 diabetes continues to be a challenging disease to manage. The addition of new agents with a positive risk–benefit ratio could potentially assist clinicians and patients in achieving adequate diabetes control. Canagliflozin, the first sodium-glucose cotransporter 2 inhibitor presently availabl...
Gardado en:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2013
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3840773/ https://ncbi.nlm.nih.gov/pubmed/24285921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S48937 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|